Trials / Completed
CompletedNCT00081614
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to assess the potential benefit of combining two targeted therapies (an anti-EGF inhibitor along with an anti-VEGF inhibitor). The goal will be to determine whether the addition of Erlotinib to Avastin will improve the benefit in metastatic renal cell carcinoma (RCC) with regard to time to progression, response rate, duration of response, and survival compared with Avastin alone. Since Avastin has been shown to be active in renal cancer, the goal will be to assess whether this activity can be enhanced with Erlotinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avastin (bevacizumab) | |
| DRUG | Tarceva (erlotinib HCl) |
Timeline
- Start date
- 2004-03-01
- Completion
- 2005-07-01
- First posted
- 2004-04-20
- Last updated
- 2014-05-16
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00081614. Inclusion in this directory is not an endorsement.